Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
39 Results for "
Pkd2
" in MedChemExpress (MCE) Product Catalog:
Products (39)
39 Results for "Pkd2" in MCE Product Catalog:
32
32 Publications Verification
Research Areas:
IKK 16 is an orally active IKK inhibitor. IKK 16 shows IC50s of 40 nM, 70 nM, 200 nM, and 50 nM for IKK2, IKK complex, IKK1, and LRRK 2, respectively. IKK 16 is also a pan-PKD inhibitor, inhibiting PKD1, PKD2, and PKD3 with IC50s of 153.9, 115, and 99.7 nM, respectively. IKK 16 is also an ABCB1 inhibitor, interfering with the binding of ABCB1 to its substrates. IKK 16 protects against LPS (HY-D1056)-induced multiple organ dysfunction by reducing the acute inflammatory response induced by endotoxin exposure. IKK 16 can restore renal function and alleviate fibrosis in acute kidney injury. IKK 16 attenuates cardiac dysfunction associated with polymicrobial sepsis in mice with type 2 diabetes mellitus (T2DM) by inhibiting the NF-κB pathway [2] .
32
32 Publications Verification
Research Areas:
IKK 16 hydrochloride is an orally active IKK inhibitor. IKK 16 hydrochloride shows IC50s of 40 nM, 70 nM, 200 nM, and 50 nM for IKK2, IKK complex, IKK1, and LRRK 2, respectively. IKK 16 hydrochloride is also a pan-PKD inhibitor, inhibiting PKD1, PKD2, and PKD3 with IC50s of 153.9, 115, and 99.7 nM, respectively. IKK 16 hydrochloride is also an ABCB1 inhibitor, interfering with the binding of ABCB1 to its substrates. IKK 16 hydrochloride protects against LPS (HY-D1056)-induced multiple organ dysfunction by reducing the acute inflammatory response induced by endotoxin exposure. IKK 16 hydrochloride can restore renal function and alleviate fibrosis in acute kidney injury. IKK 16 hydrochloride attenuates cardiac dysfunction associated with polymicrobial sepsis in mice with type 2 diabetes mellitus (T2DM) by inhibiting the NF-κB pathway [2] .
10
10 Cited Publications
Cat. No.: HY-P70499
Purity: ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: SPP1; Uropontin; Prev. BNSP; Osteopontin/Immunoglobulin Alpha 1 Heavy Chain Constant Region Fusion Protein; Prev. OPN; CDNA FLJ54682, Highly Similar To Osteopontin; Osteopontin; Secreted Phosphoprotein 1 Variant 6; Lnc-Pkd2-2-3; Bone Sialoprotein I; ETA-1; SPP1/CALPHA1 Fusion; BSPI; Bone Sialoprotein 1; Early T-Lymphocyte Activation 1; SPP-1; Urinary Stone Protein; Opn; Nephropontin; Secreted Phosphoprotein 1; Secreted Phosphoprotein 1 (Osteopontin, Bone Sialoprotein I, Early T-Lymphocyte Activation 1)
Species:
Human
Source:
HEK293
6
6
6 Cited Publications
Cat. No.: HY-P78358
Purity: ≥ 95%, as determined by reducing SDS-PAGE or Bis-Tris PAGE.
Synonyms: SPP1; Uropontin; Prev. BNSP; Osteopontin/Immunoglobulin Alpha 1 Heavy Chain Constant Region Fusion Protein; Prev. OPN; CDNA FLJ54682, Highly Similar To Osteopontin; Osteopontin; Secreted Phosphoprotein 1 Variant 6; Lnc-Pkd2-2-3; Bone Sialoprotein I; ETA-1
Species:
Mouse
Source:
HEK293
4
4 Cited Publications
Research Areas:
CRT0066101 dihydrochloride is a potent and orally active PKD inhibitor with IC50 values of 1 nM, 2.5 nM and 2 nM for PKD1, PKD2, and PKD3, respectively . CRT0066101 dihydrochloride is also a potent PIM2 inhibitor with an IC50 of ~135.7 nM. CRT0066101 dihydrochloride exhibits anti-inflammatory activity in mice LPS (HY-D1056)-induced lung injury models, and has anticancer effects [2] .
4
4 Cited Publications
Research Areas:
CRT0066101 is a potent and orally active PKD inhibitor with IC50 values of 1 nM, 2.5 nM and 2 nM for PKD1, PKD2, and PKD3, respectively . CRT0066101 is also a potent PIM2 inhibitor with an IC50 of ~135.7 nM. CRT0066101 exhibits anti-inflammatory activity in mice LPS (HY-D1056)-induced lung injury models, and has anticancer effects [2] .
4
4 Cited Publications
Cat. No.: HY-15698B
CAS No.: 1781742-22-0
Research Areas:
CRT0066101 trihydrochloride is the trihydrochloride salt form of CRT0066101 (HY-15698). CRT0066101 trihydrochloride is an orally active PKD inhibitor with IC50 values of 1 nM, 2.5 nM and 2 nM for PKD1, PKD2, and PKD3, respectively. CRT0066101 trihydrochloride is also an inhibitor for PIM2 with an IC50 of ~135.7 nM. CRT0066101 trihydrochloride exhibits anti-inflammatory activity in mice LPS (HY-D1056)-induced lung injury models, and has anticancer effects [2] .
4
4 Cited Publications
Cat. No.: HY-P71786
Purity: ≥ 90%, as determined by reducing SDS-PAGE.
Synonyms: SPP1; Uropontin; Prev. BNSP; Osteopontin/Immunoglobulin Alpha 1 Heavy Chain Constant Region Fusion Protein; Prev. OPN; CDNA FLJ54682, Highly Similar To Osteopontin; Osteopontin; Secreted Phosphoprotein 1 Variant 6; Lnc-Pkd2-2-3; Bone Sialoprotein I; ETA-1
Species:
Mouse
Source:
P. pastoris
2
2 Cited Publications
kb NB 142-70 is a potent PKD inhibitor, with IC50s of 28.3, 58.7 and 53.2 nM for PKD1, PKD2, and PKD3, respectively. kb NB 142-70 also has antitumor activity.
2
2 Cited Publications
Cat. No.: HY-P79222
Purity: ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: SPP1; Uropontin; Prev. BNSP; Osteopontin/Immunoglobulin Alpha 1 Heavy Chain Constant Region Fusion Protein; Prev. OPN; CDNA FLJ54682, Highly Similar To Osteopontin; Osteopontin; Secreted Phosphoprotein 1 Variant 6; Lnc-Pkd2-2-3; Bone Sialoprotein I; ETA-1
Species:
Rat
Source:
CHO
1
Research Areas:
RGLS4326 (RG4326) is a microRNA-17 (miR-17) oligonucleotide inhibitor with an EC50 of 28.3 nM. RGLS4326 antagonizes AMPAR and inhibits ligand binding. RGLS4326 relieves the inhibition of Pkd1/Pkd2 by miR-17 and upregulates PC1/PC2. RGLS4326 preferentially distributes to the kidney and cysts, attenuates cyst progression and improves survival in mouse models of autosomal dominant polycystic kidney disease (ADPKD) in a miR-17 binding motif-dependent manner. RGLS4326 can be used in ADPKD-related research [2] .
1
Research Areas:
RGLS4326 (RG4326) sodium is a microRNA-17 (miR-17) oligonucleotide inhibitor with an EC50 of 28.3 nM. RGLS4326 sodium antagonizes AMPAR and inhibits ligand binding. RGLS4326 sodium relieves the inhibition of Pkd1/Pkd2 by miR-17 and upregulates PC1/PC2. RGLS4326 sodium preferentially distributes to the kidney and cysts, attenuates cyst progression and improves survival in mouse models of autosomal dominant polycystic kidney disease (ADPKD) in a miR-17 binding motif-dependent manner. RGLS4326 sodium can be used in ADPKD-related research [2] .
CID 2011756 is an ATP competitive PKD inhibitor, with an IC50 of 3.2 µM for PKD1 in cell free assay, and also shows cellular pan-PKD inhibitory activity against PKD2 and PKD3 (IC50, 0.6 and 0.7 µM, respectively). CID 2011756 also has antitumor activity.
Cat. No.: HY-150364A
CAS No.: 2921918-19-4
Synonyms: RGLS8429 sodium; RG1015 sodium
Target:
Research Areas:
Farabursen sodium (RGLS8429 sodium; RG1015 sodium) is a miR-17 inhibitor. Farabursen sodium inhibits the function of the miR-17 family, relieves the inhibitory effect on miR-17 target genes including PKD1 and PKD2, and increases the level of PC1/2. Farabursen sodium slows the growth of renal cysts, reduces the ratio of kidney weight to body weight, and decreases the cyst index and proliferation index. Farabursen sodium is applicable to research related to autosomal dominant polycystic kidney disease [2].
Cat. No.: HY-150364
CAS No.: 2953012-32-1
Synonyms: RGLS8429; RG1015
Target:
Research Areas:
Farabursen (RGLS8429; RG1015) is a blood-brain barrier-permeable miR-17 inhibitor. Farabursen derepresses Pkd1 and Pkd2, the target genes of miR-17, increases the levels of PC1 and PC2, and reduces cyst growth. Farabursen decreases renal cyst growth, kidney weight-to-body weight ratio, cyst index, proliferation index, and blood urea nitrogen levels in mouse models. Farabursen is applicable to research related to autosomal dominant polycystic kidney disease [2].
Research Areas:
BPKDi is an inhibitor of PKD. BPKDi inhibits three members of the PKD family, PKD1, PKD2, and PKD3, with IC50 values of 1 nM, 9 nM, and 1 nM, respectively. BPKDi blocks signal-dependent phosphorylation and nuclear export of class IIa HDACs in cardiomyocytes and concomitantly suppresses hypertrophy of these cells .
3-IN-PP1 is a protein kinase D (PKD) inhibitor. 3-IN-PP1 has potent pan-PKD inhibitory activity for PKD1, PKD2 and PKD3 with IC50 values of 108, 94 and 108 nM, respectively. 3-IN-PP1 also is a broad spectrum anticancer agent and has inhibition of several tumor cells growth. 3-IN-PP1 can be used for the research of cancer .
Cat. No.: HY-112547
CAS No.: 1034297-58-9
Synonyms: CRT0066051
CRT5, a pyrazine benzamide, is a potent and selective inhibitor for all three isoforms of PKD in endothelial cells treated with VEGF (IC50s = 1, 2, and 1.5 nM for PKD1, PKD2, and PKD3, respectively). CRT5 decreases VEGF-induced endothelial migration, proliferation and tubulogenesis .
Cat. No.: HY-RS10591
Target:
Research Areas:
PKD2 Human Pre-designed siRNA Set A contains three designed siRNAs for PKD2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
- 1
- 2
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
